X

Trial Profile

An Open, Single-center, Stage I Clinical Study of Individualized Tumor Specific TCR-T Cells in the Treatment of Advanced Solid Tumors.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldesleukin (Primary) ; Tumour-T Cell Receptor (TCR)-Mediated T Cells therapy-Guangzhou FineImmune Biotechnology (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Guangzhou FineImmune Biotechnology

Most Recent Events

19 Sep 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
19 Sep 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Oct 2025.
11 Sep 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com